Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

BACKGROUND Although adolescent girls are the main population for prophylactic human papillomavirus (HPV) vaccines, adult women who remain at risk of cervical cancer can also be vaccinated. We report data from the interim analysis of the ongoing VIVIANE study, the aim of which is to assess the efficacy, safety, and immunogenicity of the HPV 16/18 AS04-adjuvanted vaccine in adult women. METHODS In this phase 3, multinational, double-blind, randomised controlled trial, we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control (1:1), via an internet-based system with an algorithm process that accounted for region, age stratum, baseline HPV DNA status, HPV 16/18 serostatus, and cytology. Enrolment was age-stratified, with about 45% of participants in each of the 26-35 and 36-45 years age strata and 10% in the 46 years and older stratum. Up to 15% of women in each age stratum could have a history of HPV infection or disease. The primary endpoint was vaccine efficacy against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CIN1+) associated with HPV 16/18. The primary analysis was done in the according-to-protocol cohort for efficacy, which consists of women who received all three vaccine or control doses, had negative or low-grade cytology at baseline, and had no history of HPV disease. Secondary analyses included vaccine efficacy against non-vaccine oncogenic HPV types. Mean follow-up time was 40·3 months. This study is registered with ClinicalTrials.gov, number NCT00294047. FINDINGS The first participant was enrolled on Feb 16, 2006, and the last study visit for the present analysis took place on Dec 10, 2010; 5752 women were included in the total vaccinated cohort (n=2881 vaccine, n=2871 control), and 4505 in the according-to-protocol cohort for efficacy (n=2264 vaccine, n=2241 control). Vaccine efficacy against HPV 16/18-related 6-month persistent infection or CIN1+ was significant in all age groups combined (81·1%, 97·7% CI 52·1-94·0), in the 26-35 years age group (83·5%, 45·0-96·8), and in the 36-45 years age group (77·2%, 2·8-96·9); no cases were seen in women aged 46 years and older. Vaccine efficacy against atypical squamous cells of undetermined significance or greater associated with HPV 16/18 was also significant. We also noted significant cross-protective vaccine efficacy against 6-month persistent infection with HPV 31 (79·1%, 97·7% CI 27·6-95·9) and HPV 45 (76·9%, 18·5-95·6]) Serious adverse events occurred in 285 (10%) of 2881 women in the vaccine group and 267 (9%) of 2871 in the control group; five (<1%) and eight (<1%) of these events, respectively, were believed to be related to vaccination. INTERPRETATION In women older than 25 years, the HPV 16/18 vaccine is efficacious against infections and cervical abnormalities associated with the vaccine types, as well as infections with the non-vaccine HPV types 31 and 45. FUNDING GlaxoSmithKline Biologicals SA.

[1]  D. Hendrick,et al.  Introduction , 1998, Thorax.

[2]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[3]  David R. Scott,et al.  Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA‐positive, cytologically negative women , 2002, Cancer.

[4]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[5]  Susun Bellew,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2010 .

[6]  N. Muñoz,et al.  Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial , 2009, The Lancet.

[7]  G. Zimet,et al.  Literature review of human papillomavirus vaccine acceptability among women over 26 years. , 2009, Vaccine.

[8]  K. Syrjänen.  Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines. , 2011, European journal of gynaecological oncology.

[9]  C. Wheeler,et al.  Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial , 2007 .

[10]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[11]  P. Castle,et al.  HPV vaccination: for women of all ages? , 2014, The Lancet.

[12]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[13]  H. Trottier,et al.  Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. , 2010, Cancer research.

[14]  Masha Fridman,et al.  Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study , 2011, The Lancet.

[15]  End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age , 2011, British Journal of Cancer.

[16]  N. Kiviat,et al.  Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  A. Muñoz,et al.  Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. , 2004, The Journal of infectious diseases.

[18]  S. Pagliusi,et al.  Efficacy and other milestones for human papillomavirus vaccine introduction. , 2004, Vaccine.

[19]  P. Naud,et al.  Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine , 2014, Human vaccines & immunotherapeutics.

[20]  S. Garland,et al.  Clinical update , 2022 .

[21]  B. Spiessens,et al.  Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials , 2009, Human vaccines.

[22]  D. Lowy,et al.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. , 2007, JAMA.

[23]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[24]  C. Wheeler,et al.  Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18 , 2012, International journal of cancer.

[25]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[26]  L. Pinto,et al.  Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine , 2008, Human vaccines.

[27]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[28]  J Dillner,et al.  Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland , 2007, British Journal of Cancer.

[29]  A. Kaufmann,et al.  Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study , 2014, BJOG : an international journal of obstetrics and gynaecology.

[30]  M. Sherman,et al.  Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection , 2004, Cancer Epidemiology Biomarkers & Prevention.

[31]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[32]  C. Wheeler,et al.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[33]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.

[34]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[35]  D. Lowy,et al.  HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. , 2011, Vaccine.

[36]  L. Bruni,et al.  Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. , 2010, The Journal of infectious diseases.

[37]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[38]  H. Chesson,et al.  Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. , 2011, Vaccine.

[39]  Joakim Dillner,et al.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.

[40]  W. Quint,et al.  A Human Papilloma Virus Testing Algorithm Comprising a Combination of the L1 Broad-Spectrum SPF10 PCR Assay and a Novel E6 High-Risk Multiplex Type-Specific Genotyping PCR Assay , 2013, Journal of Clinical Microbiology.

[41]  Diane Solomon,et al.  Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. , 2011, Cancer discovery.

[42]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[43]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[44]  F. Bray,et al.  Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries , 2005, Cancer Epidemiology Biomarkers & Prevention.

[45]  Sue J Goldie,et al.  Health and economic implications of HPV vaccination in the United States. , 2008, The New England journal of medicine.

[46]  W. Quint,et al.  Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.

[47]  C. Wheeler,et al.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[48]  D. Lowy,et al.  Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. , 2015, The Lancet. Oncology.

[49]  C. Wheeler,et al.  Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection , 2009, Human vaccines.

[50]  S. Wacholder,et al.  Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. , 2014, Vaccine.

[51]  S. Wacholder,et al.  Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. , 2010, Journal of the National Cancer Institute.

[52]  C. Wheeler,et al.  Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years , 2009, The Lancet.

[53]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[54]  N. Kiviat,et al.  Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections. , 2010, The Journal of infectious diseases.

[55]  S. Wacholder,et al.  Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. , 2013, American journal of epidemiology.

[56]  C. Wheeler,et al.  Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.